Source - LSE Regulatory
RNS Number : 0956D
Nuformix PLC
01 March 2022
 

1 March 2022

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Change of Auditor

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, is pleased to announce the appointment of Jeffreys Henry LLP ("Jeffreys Henry") as auditor to the Company. The appointment of Jeffreys Henry will be subject to approval by shareholders at the next Annual General Meeting of the Company.

 

The appointment of Jeffreys Henry follows the resignation of Haysmacintyre LLP who has confirmed to the Company that there are no circumstances connected with its resignation which it considers should be brought to the attention of the members or creditors of the Company. As required by the Companies Act, Nuformix will send a copy of the resignation letter to shareholders.

 

Enquiries:

 

Nuformix plc


Dr Alastair Riddell, Executive Chairman

 

Via IFC Advisory

Stanford Capital Partners Limited


Tom Price / Patrick Claridge (Corporate Finance)

+44 (0) 20 3650 3650

John Howes (Corporate Broking)

+44 (0) 20 3650 3652

 

IFC Advisory Limited


Tim Metcalfe

Zach Cohen

+44 (0) 20 3934 6630

nuformix@investor-focus.co.uk

 

About Nuformix

 

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has an early-stage pipeline of preclinical and Phase I-ready assets with potential for significant value and early licensing opportunities.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
APPEAXAPAALAEFA
Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. AJ Bell logo

Related Charts

Nuformix PLC (NFX)

0p (0.00%)
delayed 16:30PM